OGDHL and hepatocellular carcinoma: In a mouse xenograft models, oxoglutarate dehydrogenase-like (OGDHL) drove reduced carboxylation of glutamine-derived α-ketoglutaric (α-KG) acid in hepatocellular carcinoma cells by up-regulating the citric acid ratio of α-KG through retrograde tricarboxylic acid cycling.[42] It indicated that the sensitivity of HCC cells to targeted therapy could be enhanced by reducing the metabolism of glutamine.